| [1] |
Sung H，Ferlay J，Siegel RL，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin，2021，71（3）：209-249.
|
| [2] |
Hepatocellular carcinoma[J].Nat Rev Dis Primers，2021，7（1）：7.
|
| [3] |
Hilmi M，Vienot A，Rousseau B，et al.Immune Therapy for Liver Cancers[J].Cancers（Basel），2019，12（1）：77.
|
| [4] |
Kania A，Klein R.Mechanisms of ephrin-Eph signalling in development，physiology and disease[J].Nat Rev Mol Cell Biol，2016，17（4）：240-256.
|
| [5] |
Ieguchi K，Maru Y.Roles of EphA1/A2 and ephrin-A1 in cancer[J].Cancer Sci，2019，110（3）： 841-848.
|
| [6] |
Gao Z，Han X，Zhu Y，et al.Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling[J].Cell Death Dis，2021，12（5）：414.
|
| [7] |
Liang Z，Wang X，Dong K，et al.Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis：Revealing Its Importance in Chemotherapy[J].Biomed Res Int，2021，2021：5575704.
|
| [8] |
Zhang H，Li Y，Wang HB，et al.Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry[J].Nat Microbiol，2018，3（2）：1-8.
|
| [9] |
Ishigaki H，Minami T，Morimura O，et al.EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest[J].Biochem Biophys Res Commun，2019，519（4）：846-853.
|
| [10] |
Kaczmarek R，Zimmer K，Gajdzis P，et al.The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases[J].Int J Mol Sci，2021，22（9）： 4567.
|
| [11] |
Toma MI，Erdmann K，Diezel M，et al.Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma[J].PLoS ONE，2014，9（7）：e102262.
|
| [12] |
Baudet S，Bécret J，Nicol X.Approaches to Manipulate Ephrin-A：EphA Forward Signaling Pathway[J].Pharmaceuticals（Basel），2020，13（7）：140.
|
| [13] |
Iida H，Honda M，Kawai HF，et al.Ephrin-A1 expression contributes to the malignant characteristics of fetoprotein producing hepatocellular carcinoma[J].Gut，2005，54（6）：843-851.
|
| [14] |
Wada H，Yamamoto H，Kim C，et al.Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma[J].Int J Oncol，2014，45（3）：1051-1058.
|
| [15] |
Feng YX，Zhao JS，Li JJ，et al.Liver cancer：EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway[J].Hepatology，2010，51（2）：535-544.
|
| [16] |
Gómez-Maldonado L，Tiana M，Roche O，et al.EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination[J].Oncogene，2015，34（20）：2609-2620.
|
| [17] |
DamelinM，BankovichA，ParkA，etal.Anti-EFNA4Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions[J].Clin Cancer Res，2015，21（18）：4165-4173.
|
| [18] |
Wang TH，Yeh CT，Ho JY，et al.OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma[J].Mol Carcinog，2016，55（4）：366-375.
|
| [19] |
Wang TH, Ng KF, Yeh TS，et al.Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma[J].PLoS One，2012，7（7）：e41749.
|
| [20] |
Light TP，Gomez-Soler M，Wang Z，et al.A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain[J].J Biol Chem，2021，297（1）：100876.
|
| [21] |
Deng M，Tong R，Zhang Z，et al.EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma[J].Cancer Cell Int，2021，21（1）：535.
|
